Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01938248 · ClinicalTrials.gov registry record · Phase 4
Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
A Phase 4 study, sponsored by Population Health Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 4,012
- Enrollment target
NCT01938248 is a Phase 4 study that has completed, run by Population Health Research Institute. The registered enrollment target is 4,012 participants.
The verdict
NCT01938248, a Phase 4 study, has completed, sponsored by Population Health Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 4,012 participants
- Enrollment target
Study Summary
This study aims to determine if treatment with apixaban, compared with aspirin, will reduce the risk of ischemic stroke and systemic embolism in patients with device-detected sub-clinical atrial fibrillation and additional risk factors for stroke.
Interventions
- DRUG Apixaban
- DRUG aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,012 participants |
| Start Date | 2015-05 |
| Est. Completion | 2023-11-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01938248
The ClinicalTrials.gov registry entry for NCT01938248 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 4,012 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Population Health Research Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT01938248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01938248 about?
NCT01938248 is a clinical study titled "Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation". This study aims to determine if treatment with apixaban, compared with aspirin, will reduce the risk of ischemic stroke and systemic embolism in patients with device-detected sub-clinical atrial fibrillation and additional risk factors for stroke.
What is the current status of trial NCT01938248?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 4,012 participants. The study started on 2015-05. Estimated completion is 2023-11-03.
What interventions are being tested in trial NCT01938248?
The interventions under investigation include: Apixaban (DRUG), aspirin (DRUG).
Who is sponsoring clinical trial NCT01938248?
This trial is sponsored by Population Health Research Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.